Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead cMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.24
Change (%) Stock is Down 0.01 (0.24%)
Volume6,830,555
Data as of 02/09/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
02/04/16Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10Printer Friendly Version
02/01/16Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell CarcinomaPrinter Friendly Version
01/28/16Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell CarcinomaPrinter Friendly Version
01/28/16Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell CarcinomaPrinter Friendly Version
Upcoming EventsMore >>
Exelixis, Inc. at The LEERINK Partners 5th Annual Global Healthcare Conference
Wednesday, February 10, 2016 11:05 a.m. ET
Add to Calendar Add Exelixis, Inc. at The LEERINK Partners 5th Annual Global Healthcare Conference to Calendar  Help

Featured Report
Download Documentation2014 Annual Report (pdf)
Download Documentation2013 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.